These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10268554)

  • 1. The Swedish drug-event assessment methods. Special workshop--regulatory.
    Wiholm BE
    Drug Inf J; 1984; 18(3-4):267-9. PubMed ID: 10268554
    [No Abstract]   [Full Text] [Related]  

  • 2. The Australian method of drug-event assessment. Special workshop--regulatory.
    Mashford ML
    Drug Inf J; 1984; 18(3-4):271-3. PubMed ID: 10268555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardized assessment of adverse drug reactions: the method used in France. Special workshop--clinical.
    Begaud B
    Drug Inf J; 1984; 18(3-4):275-81. PubMed ID: 10268556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Food and Drug Administration algorithm. Special workshop--regulatory.
    Turner WM
    Drug Inf J; 1984; 18(3-4):259-66. PubMed ID: 10268553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Yale algorithm. Special workshop--clinical.
    Kramer MS; Hutchinson TA
    Drug Inf J; 1984; 18(3-4):283-91. PubMed ID: 10268557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmarketing surveillance for drug safety.
    Holden WL; Scarazzini LJ
    Clin Pharmacol Ther; 2004 Nov; 76(5):503; author reply 504-5. PubMed ID: 15536464
    [No Abstract]   [Full Text] [Related]  

  • 7. Switzerland's drug surveillance.
    Teuscher A; Diem P
    Lancet; 1989 Sep; 2(8663):621. PubMed ID: 2570310
    [No Abstract]   [Full Text] [Related]  

  • 8. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety.
    Qato DM; Alexander GC
    JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303
    [No Abstract]   [Full Text] [Related]  

  • 9. When can a drug be declared "safe"?
    Besag FM; Dodd S
    Curr Drug Saf; 2010 Apr; 5(2):112-3. PubMed ID: 20392200
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1294,6. PubMed ID: 10683122
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA Adds Online REMS Table.
    Aschenbrenner DS
    Am J Nurs; 2017 Nov; 117(11):21. PubMed ID: 29076851
    [No Abstract]   [Full Text] [Related]  

  • 12. Approval times and the safety of new pharmaceuticals.
    Rudholm N
    Eur J Health Econ; 2004 Dec; 5(4):345-50. PubMed ID: 15452739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
    Issa AM
    Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Legal perspectives in causality assessment.
    Freilich WB
    Drug Inf J; 1984; 18(3-4):211-7. PubMed ID: 10268552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A primer of drug safety surveillance: an industry perspective. Part II: Product labeling and product knowledge.
    Allan MC
    J Pharm Technol; 1992; 8(5):198-202. PubMed ID: 10171208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IOM advises FDA on ethics in postmarket safety trials.
    Kuehn BM
    JAMA; 2010 Aug; 304(6):627. PubMed ID: 20699450
    [No Abstract]   [Full Text] [Related]  

  • 17. Postmarketing surveillance of adverse drug reactions: problems and solutions.
    Lortie FM
    CMAJ; 1986 Jul; 135(1):27-32. PubMed ID: 3719483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rationale for a post-marketing surveillance.
    Westerholm B
    Hum Reprod; 1987 Jan; 2(1):41-4. PubMed ID: 3571446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspects of standardization as applied to the assessment of drug-event associations.
    Venulet J
    Drug Inf J; 1984; 18(3-4):199-210. PubMed ID: 10268551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What do stakeholders think about pharmacovigilance?
    Edwards IR; Graedon T
    Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.